NO20005992L - Behandling av C. Difficile toksin B assosierte tilstander - Google Patents

Behandling av C. Difficile toksin B assosierte tilstander

Info

Publication number
NO20005992L
NO20005992L NO20005992A NO20005992A NO20005992L NO 20005992 L NO20005992 L NO 20005992L NO 20005992 A NO20005992 A NO 20005992A NO 20005992 A NO20005992 A NO 20005992A NO 20005992 L NO20005992 L NO 20005992L
Authority
NO
Norway
Prior art keywords
treatment
difficile toxin
difficile
associated conditions
conditions
Prior art date
Application number
NO20005992A
Other languages
English (en)
Norwegian (no)
Other versions
NO20005992D0 (no
Inventor
Glen D Armstrong
Louis D Heerze
Original Assignee
Synsorb Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synsorb Biotech Inc filed Critical Synsorb Biotech Inc
Publication of NO20005992D0 publication Critical patent/NO20005992D0/no
Publication of NO20005992L publication Critical patent/NO20005992L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Ceramic Engineering (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
NO20005992A 1998-05-28 2000-11-27 Behandling av C. Difficile toksin B assosierte tilstander NO20005992L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/085,032 US6013635A (en) 1998-05-28 1998-05-28 Treatment of C. difficile toxin B associated conditions
PCT/CA1999/000484 WO1999061031A1 (en) 1998-05-28 1999-05-27 Treatment of c. difficile toxin b associated conditions

Publications (2)

Publication Number Publication Date
NO20005992D0 NO20005992D0 (no) 2000-11-27
NO20005992L true NO20005992L (no) 2001-01-24

Family

ID=22189033

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20005992A NO20005992L (no) 1998-05-28 2000-11-27 Behandling av C. Difficile toksin B assosierte tilstander

Country Status (10)

Country Link
US (3) US6013635A (de)
EP (2) EP1089740B8 (de)
JP (2) JP2002516284A (de)
CN (1) CN1298306A (de)
AT (1) ATE387205T1 (de)
AU (1) AU4125399A (de)
CA (1) CA2321927A1 (de)
DE (2) DE69938241T2 (de)
NO (1) NO20005992L (de)
WO (1) WO1999061031A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6034129A (en) * 1996-06-24 2000-03-07 Geltex Pharmaceuticals, Inc. Ionic polymers as anti-infective agents
US6290947B1 (en) 1997-09-19 2001-09-18 Geltex Pharmaceuticals, Inc. Ionic polymers as toxin-binding agents
US6013635A (en) * 1998-05-28 2000-01-11 Synsorb Biotech, Inc. Treatment of C. difficile toxin B associated conditions
US6358930B1 (en) * 1998-05-28 2002-03-19 Synsorb Biotech Inc. Treatment of C. difficile toxin B associated conditions
US6482402B1 (en) 1999-05-13 2002-11-19 Geltex Pharmaceuticals, Inc. Antimicrobial compositions and methods
US6867194B2 (en) 2001-08-09 2005-03-15 Wayne State University Enzyme activated nitric oxide donors
US7695738B2 (en) * 2003-02-19 2010-04-13 Academia Sinica Carbohydrate encapsulated nanoparticles
US20050287552A1 (en) * 2003-02-19 2005-12-29 Academia Sinica, Office Of Public Affairs (Technology Transfer) Carbohydrate encapsulated nanoparticle based affinity mass spectrometry
EP1633818A2 (de) * 2003-04-18 2006-03-15 MERCK PATENT GmbH Antimikrobielle pigmente
GB0321996D0 (en) * 2003-09-19 2003-10-22 Novartis Nutrition Ag Organic compounds
US7682631B2 (en) 2003-10-01 2010-03-23 Clemson University Adhesin-specific nanoparticles and process for using same
AU2004285450B2 (en) 2003-10-20 2010-01-14 Gregory K. Frykman Zeolite molecular sieves for the removal of toxins
WO2006044577A1 (en) * 2004-10-13 2006-04-27 Ilypsa, Inc. Pharmaceutical compositions comprising a toxin-binding oligosaccharide and a polymeric particle
US20060078534A1 (en) * 2004-10-13 2006-04-13 Dominique Charmot Toxin binding compositions
JP5345532B2 (ja) * 2006-08-02 2013-11-20 ヨハネス・グーテンベルク−ウニヴェルジテート・マインツ Lct中毒に対する医薬品
AU2008299885C1 (en) * 2007-09-14 2015-06-25 Sanofi Pasteur Biologics, Llc Pharmaceutical compositions containing clostridium difficile toxoids A and B
FR2964116B1 (fr) * 2010-09-01 2017-06-02 Biomerieux Sa Utilisation d'un activateur de beta-glucosidase pour la detection et/ou l'identification de c.difficile
CN102181457B (zh) * 2011-03-21 2012-07-04 王世霞 密码子优化的艰难梭菌外毒素b氨基端基因序列及其核酸疫苗
GB2491117A (en) * 2011-05-20 2012-11-28 Royal Holloway & Bedford New College Coat proteins from Clostridium and Bacillus species
CN104785019B (zh) * 2015-04-09 2017-01-11 东华大学 异形熔喷纤维制备的高效低阻空气过滤材料

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1544908A (en) * 1975-07-08 1979-04-25 Chembiomed Ltd Artificial oligosaccharide antigenic determinants
US4362720A (en) * 1977-04-14 1982-12-07 Chembiomed Ltd. Synthesis of 2-amino-2-deoxyglycoses and 2-amino-2-deoxyglycosides from glycals
US5079353A (en) * 1987-12-02 1992-01-07 Chembiomed, Ltd. Sialic acid glycosides, antigens, immunoadsorbents, and methods for their preparation
US5651968A (en) * 1991-08-23 1997-07-29 Alberta Research Council Methods and compositions for attenuating antibody-mediated xenograft rejection in human recipients
US5484773A (en) * 1994-02-14 1996-01-16 Alberta Research Council Treatment of antibiotic associated diarrhea
US5733579A (en) * 1995-04-05 1998-03-31 Abbott Laboratories Oral rehydration solution containing indigestible oligosaccharides
US5811409A (en) * 1995-06-05 1998-09-22 Synsorb Biotech, Inc. Treatment of cholera
US5637576A (en) * 1995-06-05 1997-06-10 Synsorb Biotech, Inc. Treatment of traveller's diarrhea
US5846943A (en) * 1996-11-08 1998-12-08 Synsorb Biotech, Inc. Solid support matricles containing a toxin binding oligosaccharide
ZA983690B (en) * 1998-04-02 1999-02-04 Synsorb Biotech Inc Solid support matrices containing a toxin binding oligosaccharide
US6013635A (en) * 1998-05-28 2000-01-11 Synsorb Biotech, Inc. Treatment of C. difficile toxin B associated conditions

Also Published As

Publication number Publication date
EP1089740B8 (de) 2008-05-28
DE1089740T1 (de) 2002-06-13
US6107282A (en) 2000-08-22
AU4125399A (en) 1999-12-13
CA2321927A1 (en) 1999-12-02
EP1704865A2 (de) 2006-09-27
US6465435B1 (en) 2002-10-15
CN1298306A (zh) 2001-06-06
US6013635A (en) 2000-01-11
ATE387205T1 (de) 2008-03-15
JP2002516284A (ja) 2002-06-04
WO1999061031A1 (en) 1999-12-02
DE69938241T2 (de) 2008-05-29
EP1089740B1 (de) 2008-02-27
NO20005992D0 (no) 2000-11-27
DE69938241D1 (de) 2008-04-10
EP1704865A3 (de) 2006-12-06
JP2006213735A (ja) 2006-08-17
EP1089740A1 (de) 2001-04-11

Similar Documents

Publication Publication Date Title
NO963378D0 (no) Behandling av antibiotisk assosiert diare
NO20005992D0 (no) Behandling av C. Difficile-toksin B-assosierte tilstander
TR200201745T2 (tr) Bitki hastalıklarının kontrol edilmesi için bacillus pumilus soyu
IL148079A0 (en) Human ctla-4 antibodies and compositions containing the same
AUPP437698A0 (en) Methods for treatment of coronary, carotid and other vascular disease
TW200500071A (en) Methods and reagents for treating infections of clostridium difficile and diseases associated therewith
PT764167E (pt) Inibidor biciclico de lactama do enzima de conversao da beta-interleucina-1
EP3738591A3 (de) Neuartige antibakterielle wirkstoffe
IL131238A0 (en) Pharmaceutical composition of hedgehog protein and use thereof
BR0013939A (pt) Composição farmacêutica, processo para preparação e utilização da mesma e processo para controlar ou evitar obesidade
DE69835536D1 (de) Zusammensetzungen zur behandlung von staphylococcus aureus infektionen
WO2001032219A3 (en) Treatment of c. difficile toxin b associated conditions
MXPA02003398A (es) Composiciones aromatizantes antimicrobianas.
PH12021552875A1 (en) METHODS AND COMPOSITIONS COMPRISING STAPHYLOCOCCUS PROTEIN A (SpA) VARIANTS
BRPI0416088A (pt) composição, sistema, e método de tratar condições tais como calcificação vascular
MX9708611A (es) Compuestos de dialquiltiacumicina.
ES2163186T3 (es) Composicion que comprende mupirocina y clorhexidina.
PT796618E (pt) Tratamento e profilaxia da pancreatite
HU910705D0 (en) Medical preparation
CA2020704A1 (en) Hydrophobically modified polycarboxylate polymers utilized as detergent builders
PT999851E (pt) Utilizacao de um enzima para a producao de um agente para controlo da infeccao bacteriologica
NO943765L (no) Aryloksybenzen-herbicidmidler
ES2193421T3 (es) Composicion de blanqueo enzimatica.
MXPA03001986A (es) Composiciones antitromboticas.
AU2768697A (en) Acyl urea compounds for the treatment of coccidioidomycosis in warm-blooded animals

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application